Title | Increased yield of endothelial cells from peripheral blood for cell therapies and tissue engineering. |
Publication Type | Journal Article |
Year of Publication | 2015 |
Authors | RM Jamiolkowski, SD Kang, AK Rodriguez, JM Haseltine, LJ Galinat, AE Jantzen, TA Carlon, MD Darrabie, AJ Arciniegas, JG Mantilla, NR Haley, M Noviani, JD Allen, TV Stabler, JW Frederiksen, O Alzate, LG Keil, S Liu, F-H Lin, GA Truskey, and HE Achneck |
Journal | Regenerative Medicine |
Volume | 10 |
Issue | 4 |
Start Page | 447 |
Pagination | 447 - 460 |
Date Published | 05/2015 |
Abstract | <h4>Aim</h4>Peripheral blood-derived endothelial cells (pBD-ECs) are an attractive tool for cell therapies and tissue engineering, but have been limited by their low isolation yield. We increase pBD-EC yield via administration of the chemokine receptor type 4 antagonist AMD3100, as well as via a diluted whole blood incubation (DWBI).<h4>Materials & methods</h4>Porcine pBD-ECs were isolated using AMD3100 and DWBI and tested for EC markers, acetylated LDL uptake, growth kinetics, metabolic activity, flow-mediated nitric oxide production and seeded onto titanium tubes implanted into vessels of pigs.<h4>Results</h4>DWBI increased the yield of porcine pBD-ECs 6.6-fold, and AMD3100 increased the yield 4.5-fold. AMD3100-mobilized ECs were phenotypically indistinguishable from nonmobilized ECs. In porcine implants, the cells expressed endothelial nitric oxide synthase, reduced thrombin-antithrombin complex systemically and prevented thrombosis.<h4>Conclusion</h4>Administration of AMD3100 and the DWBI method both increase pBD-EC yield. |
DOI | 10.2217/rme.15.2 |
Short Title | Regenerative Medicine |